#Screening-Tool
I try and buy used to get around the ethically sourcing issue but that isn't really a solution nor can it work for everyone. Thanks for the additional screening tool for buying new.
November 20, 2026 at 10:52 PM
when new hEDS criteria comes out i also wanna separate out the hEDS screening tool with a version people can bring to their normal PCPs maybe? like a clean "doctor take me seriously please" version
November 16, 2026 at 8:36 PM
The moment that you realize you have married a moron.

Therr should be a pre-nup psych screening tool.

But, her name is Karen.
November 20, 2026 at 2:17 AM
Do you think mitch could pass what tRump calls a cognitive test and the rest of the world calls the dementia screening tool called the Montreal Cognitive Assessment (MoCA)? What do tRump and maga think about it, they had a lot to say about Biden?
Three men are paid for moving a vegetable around 🤦‍♂️
November 18, 2026 at 3:28 PM
LLM screening numbers swing a lot between studies. One model screening abstracts alone found 3 of the 17 included studies (The Laryngoscope). A lightweight open-source one reached 90% to 95% sensitivity (JAMIA Open). Your review isn't theirs, so pilot the tool on records you've already screened.
November 18, 2026 at 10:24 PM
True, but they start with temperature screening. I'm confident a quick screening tool, like the test for Covid, could be developed quite quickly.
November 19, 2026 at 5:51 PM
🌟 For #NationalSelfCareWeek, we're highlighting a study we're proud to support that aims to develop a new tool to help identify older people who may be at risk of social frailty, loneliness, and isolation. 🏡'The Social Frailty Screening Tool'
November 16, 2026 at 7:01 AM
Residents can also use the MI WEST screening tool linked below to answer questions about their individual circumstances and determine whether they may qualify for an exemption or already meet the requirement.

www.michigan.gov/mdhhs/assist...
Michigan Work & Exemption Screening Tool
Learn about Federal changes to Medicaid and Food Assistance Programs..
www.michigan.gov
November 19, 2026 at 10:00 PM
yes this is basically what i'm trying to make accessible for people, for context this is about a hEDS screening tool i programmed into my visual novel that uses the official criteria with explanations for each point. i went to a rheuma and several other docs and they didn't do anything unfortunately
November 21, 2026 at 1:02 AM
Developing a screening tool for cognitive deficits in routine neuro-oncology clinical practice: Clinical feasibility and cognitive insight. @velindrecc.bsky.social academic.oup.com/nop/article/...
Developing a screening tool for cognitive deficits in routine neuro-oncology clinical practice: Clinical feasibility and cognitive insight
AbstractBackground. Cognitive impairments are common in brain tumor patients and cause significant impact on quality of life. Early detection is imperative
academic.oup.com
November 20, 2026 at 9:58 AM
One UI 9.5 lets you set custom greetings for AI-powered call screening www.sammobile.com/news/one-ui-...
One UI 9.5 lets you set custom greetings for AI-powered call screening
Get an early look at the new Custom Greeting feature coming to Samsung's AI Call Screening tool with the One UI 9.5 update.
www.sammobile.com
November 16, 2026 at 4:56 PM
Sadly I can't find the piece I wrote around 2007 on how I diagnosed myself at a few weeks postpartum as a sex addict and also the problem with the Sexual Addiction Screening Test (a main tool being promoted). But you can see it (and all it's problems) here psychology-tools.com/test/sast
November 17, 2026 at 11:40 AM
New tool: Domain Report. One page for any .com name: score, offensive-meaning screening, social handles, availability and, if registered, its health. Every name has its own address to paste to a co-founder.

https://namedaemon.com/tools/domain-report/?utm_source=bsky&utm_campaign=nd30
November 18, 2026 at 7:00 AM
In 200 high-risk patients, twice-weekly plasma PCR detected occult MCM in 2.5%; sensitivity 83.3%, specificity 99.6%, NPV 99.9%. Positive results prompted antifungal therapy after median 1 day.
A Multicenter Interventional Trial Using Blood Mucorales Polymerase Chain Reaction as a Screening Tool in High-Risk Hematology Patients (MUCOPS)
Mucormycosis (MCM) is a life-threatening invasive mold infection. Conventional diagnostics are insensitive. Mucorales polymerase chain reaction (PCR) shows promising diagnostic accuracy, and early blood PCR detection may improve survival. Prospective screening data remain limited.MethodsMUCOPS was a prospective multicenter interventional study in Belgium. Adults receiving remission-induction chemotherapy for acute myeloid leukemia or myelodysplastic syndrome, or first allogeneic hematopoietic cell transplantation, underwent twice-weekly plasma Mucorales PCR screening (MucorGenius®) for 3 months from treatment initiation. Primary endpoints were the incidence of a positive screening PCR and diagnostic performance. Results were reported within 24–48 hours and integrated into routine care, with performance evaluated against clinical, radiological, and microbiological data.ResultsTwo hundred patients underwent 2400 plasma PCR tests (median 9 per patient, IQR 6–17); 12 (6.0%) had a positive screening PCR. Five otherwise occult MCM cases (2.5%) were identified: 3 by plasma PCR and 2 by bronchoalveolar lavage fluid (BALF) PCR only. Plasma PCR sensitivity was 83.3%, specificity 99.6%, positive predictive value 52.6%, and negative predictive value (NPV) 99.9%. Positive results triggered investigations and early liposomal amphotericin B (median 1 day, IQR 0.5–2). Three patients had concomitant invasive aspergillosis. In survivors, PCR clearance occurred within 4–7 days.ConclusionsTwice-weekly plasma Mucorales PCR screening was feasible in high-risk hematology patients, with good sensitivity and excellent specificity and NPV, effectively ruling out MCM. Isolated BALF positivity highlights uncertain clinical significance. Screening detected otherwise occult MCM, enabled early antifungal therapy, and influenced clinical management. These findings support incorporating plasma Mucorales PCR into future definitions and management strategies.Clinical trial registrationNCT05925660.
academic.oup.com
November 21, 2026 at 1:30 AM
The “CrysVCD” tool developed at MIT could cut the huge amounts of time and money spent on screening out chemically unstable designs... Read more
November 19, 2026 at 2:30 AM
In a tool-search experiment, rare targets were missed more often. Twelve volunteers; not an airport screening score.
https://wildlymeasured.com/research/search-costs/
Research attribution: @visualattentionlab.bsky.social.
November 19, 2026 at 8:12 AM
Check out this case study exploring the progress made by APA member Greater Manchester Mental Health NHS Foundation Trust in implementing the Assist-Lite screening tool.

Read more about it here: www.nhsapa.org/downloads/as...
Case study - Assist Lite | NHS APA
www.nhsapa.org
November 16, 2026 at 4:30 PM
How to interpret first two weeks of ads for CV screening tool? — https://infonesia.fyi/knowledge/how_to_interpret_first_two_weeks_of_ads_for_cv_screening_tool.php
November 15, 2026 at 4:59 PM
Revolutionizing Healthcare: At-Home HPV Cancer Screening Just Got Easier with Simple HealthKit and Waters Corporation#United_States#Milpitas#Waters_Corporation#HPV_Screening#Simple_HealthKit
Revolutionizing Healthcare: At-Home HPV Cancer Screening Just Got Easier with Simple HealthKit and Waters Corporation
Simple HealthKit partners with Waters Corporation to provide a groundbreaking at-home HPV cervical cancer screening tool, enhancing patient access and care.
third-news.com
November 17, 2026 at 12:36 PM
J Participatory Med: CareCheck, a #digital Risk Screening Tool for Family Caregivers in Gynecologic Oncology Care Settings: Usability #study
CareCheck, a #digital Risk Screening Tool for Family Caregivers in Gynecologic Oncology Care Settings: Usability #study
Background: Providing care to a family member or friend with a serious illness like cancer increases the risk for poor physical, psychological, and functional health outcomes. Despite their critical role, family caregivers (FCGs) are rarely screened in clinical settings for the wide range of factors that may put them and the person they care for at risk for poor outcomes. Mobile health (mHealth) apps can efficiently facilitate access to high-quality health information for FCGs; however, few are clinically integrated. Objective: This #study aimed to evaluate the usability of CareCheck, an mHealth-based #digital risk screening tool designed to enable FCGs' self-awareness of potential caregiving-related risks for adverse health and psychosocial outcomes and to support health care professionals in personalizing interventions that address FCGs' specific risk factors. Methods: This usability #study of CareCheck was conducted between June and August 2023 at a large academic medical center, using two evaluation methods: (1) quantitative measurement with a modified 5-item Mobile Health App Usability Questionnaire (MAUQ) and (2) exploratory qualitative content analysis based on feedback from FCGs and trained staff. FCGs of #patients seen in gynecologic oncology care settings were recruited through two pathways: (1) a convenience sample of caregivers approached in the out#patient clinic waiting area and (2) caregivers receiving support through the institution's Family Caregiver Advocacy, Research, and Education (CARE) Center. #participants completed CareCheck and the usability questionnaire via a tablet-based mHealth app, with an interview-administered option available for those who were assessed via telephone. Trained staff from the CARE Center held a dual role in the #study: they helped administer CareCheck to FCGs, and they also #participated as respondents themselves, offering their own perspectives on CareCheck's clinical usability and workflow fit, which were analyzed alongside FCG data. Results: A convenience sample of 56 FCGs and 2 trained staff #participated in the usability #study. Of the 56 FCGs, 54 completed the usability questionnaire; the mean MAUQ score was 6.49 (SD 1.06) out of 7, indicating high usability. Qualitative analysis identified recommendations in 2 areas: (1) perceptions of CareCheck's usability and functionality and (2) clinical implementation considerations for CareCheck. Conclusions: FCGs and staff found CareCheck to be user-friendly and easy to navigate. While further iterations are needed to refine content and optimize integration with clinical workflows, CareCheck demonstrated potential as a clinically integrated tool for identifying and addressing FCG risk for poor social, psychological, or health outcomes in gynecologic oncology care settings.
dlvr.it
November 20, 2026 at 9:37 PM
Have you realized that we’re already more than halfway through November? This means that you have less than one month to secure your tickets with the best pricing! Visit shorturl.at/8SFC2 for more info.
Perturb 2027 | High-content CRISPR screening conference
CRISPR screens have become a key tool in drug discovery. Join us at Perturb 2027, as we explore the applications of high-content CRISPR screening methods.
shorturl.at
November 18, 2026 at 3:41 PM
Beyond screening for pulmonary arterial hypertension: The DETECT score is a potential promising prediction tool for all-cause mortality in systemic sclerosis: Analysis from the EUSTAR database scientiasalut.gencat.cat/handle/11351... #ScientiaVH
scientiasalut.gencat.cat
November 17, 2026 at 12:19 PM
An India-based AI startup (Froncort.AI) used its AI-NETRA tool to run a promising TB screening pilot with Maharashtra's State TB Office and FIND. They found a similar # of positives while screening ~63% fewer people. They received $2.3M from google.org to develop its mobile extension (mAI-NETRA).
November 16, 2026 at 11:16 PM